anonymous
Guest
anonymous
Guest
Nothing new to discuss and now we're losing any last hope to differentiate us vs them.
Sounds like you give up, move on so someone else can sell in that territory who actually believesNothing new to discuss and now we're losing any last hope to differentiate us vs them.
Market share don't lieSounds like you give up, move on so someone else can sell in that territory who actually believes
How bad is itMarket share don't lie
These KAS roles are a complete waste. Our executive leadership has become deaf and blind. This will waste our time and piss off our customers. What a waste of resources.And now the shut down of a clinical trial coupled with the stock hit a few weeks ago. Paying for all these added people to our once lean- mean sales force will be a recipe for disaster once the next quarterly earnings come out. Loosing share weekly to freaking Teva and Austedo won't pay the bills for all these new re-treads we are hiring. Just damn, can we hold off on all these territory overlaps!
Somebody did not get hired.These KAS roles are a complete waste. Our executive leadership has become deaf and blind. This will waste our time and piss off our customers. What a waste of resources.
Agree. Not needed at this time with one product and 3 teams already!These KAS roles are a complete waste. Our executive leadership has become deaf and blind. This will waste our time and piss off our customers. What a waste of resources.
Well we already pissed off one of our lead investigators and trial study author over access, May as well piss off the rest.Agree. Not needed at this time with one product and 3 teams already!
Or you could go get another job and save us your whiningOn another note, what do we do if our company vehicle just got flooded with storm surge from Milton? Oh wait, that was my previous pharma job where we actually had a company vehicle that didn't cost us a dime to drive. I guess I'll be paying a higher car insurance premium that my weak-ass car allowance won't cover.
Nope, I'll just stay and keep this cush job and whine as much as I want.Or you could go get another job and save us your whining
It's going to be interesting on our next earnings call when the shareholders question Austedo's dominance in market share takeover. It was just 10 months ago or at the end of last year where our glorious leader told the street that we would never relinquish that position in the VMAT2 class.Or you could go get another job and save us your whining
Ya, most of my scripts are patient assistance now. Do we have a plan? I feel like the company is giving up.It's going to be interesting on our next earnings call when the shareholders question Austedo's dominance in market share takeover. It was just 10 months ago or at the end of last year where our glorious leader told the street that we would never relinquish that position in the VMAT2 class.
Yes, the plan is continue to sell our patient assistance!Ya, most of my scripts are patient assistance now. Do we have a plan? I feel like the company is giving up.
Not a good plan.Yes, the plan is continue to sell our patient assistance!